The companies will commercialize Predigraft, a data analysis tool that provides early predictions of risk for allograft rejection and transplant loss.
The firm reported that test volumes for its Cologuard colorectal cancer screening test also rose 79 percent year over year.
The companies will standardize and automate Qiagen's QuantiFeron-TB Gold Plus test workflow on Tecan's Fluent laboratory automation workstation.
Test volume for the firm's Cologuard colorectal cancer screening test rose 49 percent year over year during the quarter.
Pfizer will join Exact's sales reps to increase adoption of the colorectal cancer test; Wall Street reacted by sending Exact's shares up sharply.
The companies will market Agena's MassArray Dx system with HeartGenetics' HeartDecode genetic testing software and cardiovascular assays.
The test, which went off the market when its original seller closed shop, uses an ultracentrifuge and spectrophotometer to measure cholesterol and triglycerides.
The arrangement will allow Illumina to market and promote Kailos' research solutions for pharmacogenetic target enrichment.
ASI's CEO said the clearance gives labs a system that eliminates the need for costly internal validation.